you're cherry picking facts when you suggest the chance of this type of trial to be successful is only 13.2%. That percentage is the overall chance of success from pre clinical all the way to market. The following percentage is only from memory but phase 2 success is an average of circa 45% whilst phase 3 I believe is circa 55%. A lot of the reason for these failures is safety and efficacy. We are proved both.
Also, as index said, there is no xanahes. If I were to take a guess I would suggest they are finalising the target occupancy data and awaiting grants and also waiting for covid affected universities which we will be partnering with to reopen.
I am as disappointed as you about the delay but their international trials are up in the air, as are their grant applications and target occupancy was only due to finish now.
ACW Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
(20min delay)